- ►urotoday.com [PDF] H Holdaas, B Fellström, AG Jardine, I … - The Lancet, 2003 - Elsevier We did a multicentre, randomised, double-blind, placebo-controlled trial in 2102
renal transplant recipients with total cholesterol 4·0–9·0 mmol/L. We
randomly assigned patients fluvastatin (n=1050) or placebo (n=1052) and ... Cited by 292 - Related articles - All 14 versions
- ►ahajournals.org H Fukuta, DC Sane, S Brucks, WC Little - Circulation, 2005 - Am Heart Assoc Methods and Results— We evaluated 137 patients with HF and an EF 0.50. The
effect of treatment received at study entry on survival was determined. During a
follow-up of 21±12 months, 20 deaths were observed. Treatment with an ACE ... Cited by 143 - Related articles - All 10 versions
- ►asnjournals.org M Tonelli, L Moye, FM Sacks, T Cole, GC … - Journal of the American Society of Nephrology, 2003 - Am Soc Nephrol Hyperlipidemia has been hypothesized to play an important role in the
progression of renal insufficiency, either through toxic effects of lipids on
mesangial cells or by promoting intrarenal atherosclerosis (8–10). In ... Cited by 126 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org M Tonelli, C Isles, GC Curhan, A Tonkin, MA … - Circulation, 2004 - Am Heart Assoc From the Divisions of Nephrology and Critical Care Medicine, University of
Alberta, and the Institute of Health Economics, Edmonton, Alberta, Canada (MT);
Department of Medicine, Dumfries and Galloway Royal Infirmary, Dumfries, ... Cited by 130 - Related articles - BL Direct - All 13 versions
- ►onlinejacc.org J Ezekowitz, FA McAlister, KH Humphries, CM … - Journal of the American College of Cardiology, 2004 - Elsevier Renal insufficiency is associated with poorer outcomes in patients with HF, but
the mechanisms are uncertain. In particular, the degree of therapeutic nihilism
in these patients, and whether it is appropriate, is unclear. Cited by 87 - Related articles - BL Direct - All 10 versions
A Corsini - Cardiovascular drugs and therapy, 2003 - Springer Summary. Controlled clinical studies and clinical experi- ence over many years
have proven that virtually all patients benefit from lipid-lowering therapy with
statins, even those with normal LDL cholesterol levels. Several recent ... Cited by 54 - Related articles - BL Direct - All 5 versions
J Coresh, B Astor, MJ Sarnak - Current opinion in nephrology and hypertension, 2004 - journals.lww.com Purpose of review Chronic kidney disease is becoming recognized as an important
risk factor for cardiovascular disease. Recent publications on cardiovascular
disease risk in chronic kidney disease, cardiovascular disease risk factors ... Cited by 56 - Related articles - BL Direct - All 7 versions
- ►asnjournals.org WM McClellan, RD Langston, R Presley - Journal of the American Society of Nephrology, 2004 - Am Soc Nephrol ABSTRACT. The risk of progression to ESRD among individuals with cardiovascular
disease and chronic kidney disease (CKD) is not well defined. The purpose of
this study was to describe the risk of ESRD among patients with ... Cited by 54 - Related articles - BL Direct - All 5 versions
P Stenvinkel - Contrib Nephrol, 2005 - content.karger.com Abstract Cardiovascular disease (CVD) remains the major cause of morbidity and
mortality in end-stage renal disease (ESRD) patients. As traditional risk
factors cannot alone explain the unacceptable high prevalence and incidence ... Cited by 47 - Related articles - All 6 versions
NS Anavekar, MA Pfeffer - Kidney International, 2004 - nature.com Patients with CKD experience higher mortality and adverse cardiovascular (CV)
event rates, which remains significant after adjustment for conventional
coronary risk factors. This progressive CV risk associated with worsening ... Cited by 45 - Related articles - All 4 versions
